PHAXIAM Therapeutics (PHAXIAM Therapeutics) Debt-to-EBITDA : 0.00 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PHAXIAM Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PHAXIAM Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. PHAXIAM Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. PHAXIAM Therapeutics's annualized EBITDA for the quarter that ended in Sep. 2023 was $-22.94 Mil. PHAXIAM Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PHAXIAM Therapeutics's Debt-to-EBITDA or its related term are showing as below:

PHXM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.02 Med: -0.11 Max: 3.85
Current: -1.02

During the past 11 years, the highest Debt-to-EBITDA Ratio of PHAXIAM Therapeutics was 3.85. The lowest was -1.02. And the median was -0.11.

PHXM's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs PHXM: -1.02

PHAXIAM Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for PHAXIAM Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics Debt-to-EBITDA Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.05

-0.24

-0.42

-0.55

3.85

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial															0.07	-	1.65	N/A	-

Competitive Comparison of PHAXIAM Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, PHAXIAM Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's Debt-to-EBITDA falls into.

PHAXIAM Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PHAXIAM Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3.538	+	10.834)	/	3.729
	=	3.85

PHAXIAM Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-22.944
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

PHAXIAM Therapeutics (NAS:PHXM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

PHAXIAM Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (PHAXIAM Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (NAS:PHXM) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

PHXM:France 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.